CSL Limited

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical products and vaccines. The company operates through three segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment focuses on manufacturing, marketing, and distributing plasma products, gene therapies, and recombinants. The CSL Seqirus segment is responsible for manufacturing, marketing, and distributing influenza-related products and providing pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products primarily in the therapeutic areas of iron deficiency and nephrology. CSL Limited's therapeutic areas include Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. The company also licenses its intellectual property and develops vaccines for the prevention of infectious diseases. CSL Limited has a strategic collaboration with Dutch biotech company VarmX BV to develop VMX-C001, which aims to help restore blood coagulation in patients requiring urgent surgery. The company distributes its products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. CSL Limited was founded in 1916 as Commonwealth Serum Laboratories Limited, changing its name to CSL Limited in October 1991, and is headquartered in Melbourne, Australia.